They represent a high-risk group requiring careful monitoring and aggressive supplementation as needed
When you reach a stable routine, you and your clinician can discuss maintenance : continuing the medication, tapering, or transitioning to a non-medication plan
Yunfeng Liu, [email protected] These authors have contributed equally to this work and share first authorship These authors have contributed equally to this work This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology ORCID: Yi Zhang, orcid.org/0000-0003-0305-3127 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
The figures below are approximate ranges and can vary by surgeon, hospital, and scope of the procedure
Meanwhile, Pfizer $PFE announced Wednesday another cost-cutting initiative as the company struggles with diminishing demand for its COVID-19 vaccine
GLP-1 RAs mimic the action of the endogenous incretin hormone GLP-1 by activating GLP-1 receptors in pancreatic -cells
